搜索结果: 1-15 共查到“Immunotherapy”相关记录53条 . 查询时间(0.359 秒)
Data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer（图）
晚期肺癌 免疫治疗 停止治疗
2023/6/27
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival fo...
周蓉蓉教授团队在国际著名期刊Journal for ImmunoTherapy of Cancer上发表肺腺癌脑转移免疫微环境的原创性科研成果（图）
肿瘤科 国际著名期刊 肺腺癌 肿瘤免疫治疗
2023/5/26
近日，中南大学湘雅医院肿瘤科周蓉蓉教授脑转移MDT团队在国际著名期刊Journal for ImmunoTherapy of Cancer（肿瘤免疫治疗期刊，IF=12.485）以论著形式在线发表了题为“Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negativ...
Immunotherapy — drug treatment that stimulates the immune system to attack tumors — works well against some types of cancer, but it has shown mixed success against lung cancer.
Journal for ImmunoTherapy of Cancer丨罗敏/卢智刚团队报道瘤内注射激活STING的纳米疫苗提高抗肿瘤免疫效果（图）
卢智刚团队 肿瘤免疫 生物医学研究院
2023/4/14
整合含有天然免疫刺激分子的纳米制剂、以及个性化新抗原筛选技术，使肿瘤疫苗在临床测试展现了令人瞩目的有效性。新一代的肿瘤疫苗与CAR技术﹑免疫检查点干预成为免疫治疗中重要的三大板块。然而，在很多病人中，T细胞无法通过肿瘤屏障进入瘤内，导致对多种免疫治疗的不敏感；因此促进T细胞进入肿瘤，逆转肿瘤微环境成为提高免疫治疗效果的重要步。
Method for delivering immune system-stimulating drugs may enhance cancer immunotherapy（图）
递送 免疫系统 刺激药物 癌症免疫治疗
2023/6/7
Stimulating the body’s immune system to attack tumors is a promising way to treat cancer. Scientists are working on two complementary strategies to achieve that: taking off the brakes that tumors put ...
徐建青、张晓燕教授团队《Journal for ImmunoTherapy of Cancer》报道一种全新的、肿瘤微环境激活杀伤的CAR-T，有潜力成为不同实体瘤有效治疗手段（图）
张晓燕教授 生物医学研究院 实体瘤 CAR-T疗法
2023/4/14
近年来，CAR-T疗法治疗血液源性肿瘤效果显著，然而在针对实体瘤的临床研究中却遭遇重大挑战。目前CAR-T均为靶点激活杀伤，而肿瘤靶点通常也在正常组织低表达，进而产生“on-target, off-tumor”现象、诱生炎症因子风暴、中枢神经毒性等，给CAR-T治疗带来严重的安全隐患。肿瘤细胞的异质性进一步导致靶点激活杀伤有效性受到挑战。即目前的靶点激活杀伤的CAR-T技术在在治疗实体瘤中，安全性...
Sachin Bhagchandani, a graduate student in the Department of Chemical Engineering currently working at the Koch Institute for Integrative Cancer Research, has won the National Cancer Institute Predoct...
许杰课题组《Journal for Immunotherapy of Cancer》揭示THADA在驱动PD-L1高尔基体驻留中的作用以及肿瘤免疫靶标价值（图）
许杰课题组 癌细胞 免疫检查点
2023/4/17
癌细胞中程序性死亡配体1（PD-L1）的异常上调抑制T细胞介导的细胞毒性，但驱动和维持PD-L1表达的分子机制仍不完全清楚。PD-L1在肿瘤细胞内高尔基体等细胞器的驻留可能是影响抗体药物疗效的因素之一，但既往对其理解并不充分，使免疫检查点阻断疗法面临挑战。
徐建青/张晓燕团队在《Journal for ImmunoTherapy of Cancer》报道IL-21重组溶瘤痘苗病毒单独或联合免疫细胞疗法具有强效抗肿瘤作用（图）
溶瘤病毒 冷肿瘤 热肿瘤 牛痘病毒天坛株
2023/4/17
溶瘤病毒是天然的或经人工改造的、能在肿瘤组织中优势复制、直接或间接抑制肿瘤细胞生长的一类病毒。溶瘤病毒主要通过以下途径发挥抗肿瘤功能：（1）病毒在肿瘤细胞内复制导致肿瘤细胞直接杀伤；（2）病毒感染肿瘤细胞后激发并释放细胞因子，重塑肿瘤免疫微环境、趋化免疫细胞浸润到肿瘤组织，促进“冷肿瘤”向“热肿瘤”转变；（3）裂解的肿瘤细胞释放特异性抗原，与细胞因子协同，提升机体抗肿瘤特异性免疫反应；（4）溶瘤病...
树突状细胞（DC）疫苗是目前在临床上应用的一种肿瘤治疗疫苗，其制备过程一般都在病人体外进行，病人来源的DC在体外进行诱导分化后再回输给病人，这种疫苗制备过程十分复杂，容易被污染，不同的技术人员、不同条件的实验室制备的疫苗疗效差异较大，较难标准化，因此体外制备的DC疫苗很难在临床推广应用。
2020年4月16日，Journal for ImmunoTherapy of Cancer (JITC)杂志在线发表了上海交通大学医学院上海市免疫学研究所李斌课题组和复旦大学附属妇产科医院乳腺外科吴克瑾课题组合作的成果“Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast canc...
Researchers Develop A Remote-Controlled Cancer Immunotherapy System（图）
Researchers Remote-Controlled Cancer Immunotherapy System
2018/2/1
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.There ...
Institute for Advanced Study Scholars Develop First Mathematical Model For Predicting Patient Response to Immunotherapy（图）
Institute for Advanced Study Scholars First Mathematical Model Predicting Patient Response Immunotherapy
2017/11/23
Institute for Advanced Study scholars and collaborators have created the first mathematical model to predict how a cancer patient will respond to immunotherapy, according to a study published in Natur...
2017冷泉港亚洲会议：肿瘤免疫学和免疫治疗（Cold Spring Harbor Asia conference on Tumor Immunology & Immunotherapy）
Tumor Immunology Immunotherapy
2017/1/17
We are pleased to announce the Cold Spring Harbor Asia conference on Tumor Immunology & Immunotherapy which will be held in Suzhou, China, located approximately 60 miles west of Shanghai. The conferen...
2017癌症免疫和免疫治疗 Keystone Symposia（2017 Keystone Symposia on Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology）
Cancer Immunology Immunotherapy
2017/1/13
The meeting will begin on Sunday, March 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 23 with a closing plenary sessio...